Q2 2025 Autolus Therapeutics PLC Earnings Call Transcript
Key Points
- Autolus Therapeutics PLC (AUTL) reported strong product sales of $20.9 million in Q2 2025, bringing the total for the first six months to $29.9 million, indicating good momentum in the launch of AUCATZYL.
- The company has expanded its center presence with 46 centers authorized for AUCATZYL use and 90% of total US medical lives covered, on track to reach 60+ centers by year-end.
- Autolus received conditional marketing authorization for AUCATZYL in the UK and from the European Commission, with ongoing market access discussions in the UK.
- The FELIX data showed favorable maturation with a median duration of response reaching 42.6 months and a plateau in overall survival forming at around 40%.
- The company is well-capitalized with $454.3 million in cash, cash equivalents, and marketable securities, supporting the launch and commercialization efforts.
- The CMS decision on split reimbursement led to a change in revenue recognition and administrative adjustments at medical centers, slowing patient enrollment, with impacts expected to resolve by Q4.
- Cost of sales in Q2 2025 was $24.4 million, higher due to commercial product delivery costs, canceled orders, and idle capacity, impacting gross margins.
- Autolus does not expect EU sales in 2025 and 2026 due to the need for disciplined market access evaluation and economic viability considerations.
- The company reported a net loss of $47.9 million for Q2 2025, although reduced from the previous year, indicating ongoing financial challenges.
- There is uncertainty and complexity in navigating European market access processes, particularly due to methodological challenges in pricing and reimbursement for cell and gene therapies.
Good day, and thank you for standing by. Welcome to the Autolus second quarter 2025 financial results conference call. (Operator Instructions) Please be advised today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Amanda Cray, Executive Director, Investor Relations, please go ahead.
Thank you, Kevin. Good morning, or good afternoon, everyone, and thank you for joining us on today's call. With me our Chief Executive Officer, Dr. Christian Itin; and Chief Financial Officer, Rob Dolski.
I'd like to remind you that during today's call, we will make statements related to our business that are forward-looking under Federal securities laws and the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to, statements regarding status of the ongoing commercial launch of AUCATZYL; Autolus' manufacturing, sales, and marketing plans for AUCATZYL; the market
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
